– FRANCE, Suresnes – Gradient Denervation Technologies, a medical device company developing a minimally-invasive, ultrasound-based catheter system, announced the appointment of Stanton Rowe to its board of directors.
“I’m delighted to have Stan joining us and am looking forward to leveraging his deep experience to help guide the company in our next phase.” said CEO Martin Grasse.
About Stanton Rowe
Stanton Rowe has developed multiple innovative medical technologies through his current incubator, Nidus Biomedical, and with his prior incubator, NXT Biomedical. He served as CSO of Edwards Lifesciences and was co-founder and CEO of Percutaneous Valve Technologies, the developer of the first transcatheter aortic valve replacement device which was later acquired by Edwards.
“I’m very excited to join Gradient and work with the company to bring this technology to patients,” said Stanton Rowe. “Gradient’s early experience with pulmonary denervation is promising and I see great potential for this system to provide a new treatment option for these underserved patients.”
About Gradient Denervation Technologies
Gradient Denervation Technologies is developing a minimally invasive device for the treatment of pulmonary hypertension in patients with heart failure. Gradient leverages intellectual property developed at Stanford University. The Gradient device is for investigational use only and is not approved for commercial use anywhere in the world.
Gradient also announced that the Food and Drug Administration has approved the expansion of the PreVail-PH2 Early Feasibility Study based on the results from the initial cohort. The study is actively enrolling patients with WHO Group 2 Pulmonary Hypertension at centers in the United States and is recruiting additional clinical centers with heart failure and pulmonary hypertension expertise.
For more: https://www.gradientdenervation.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.